BiotechTube

tredaptive (nicotinic acid/ laropiprant) + placebo

ApprovedCompleted
1 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Polycystic Ovary Syndrome

Conditions

Polycystic Ovary Syndrome

Trial Timeline

Jun 1, 2010 → May 1, 2012

NCT ID
NCT01118598

About tredaptive (nicotinic acid/ laropiprant) + placebo

tredaptive (nicotinic acid/ laropiprant) + placebo is a approved stage product being developed by Merck for Polycystic Ovary Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT01118598. Target conditions include Polycystic Ovary Syndrome.

What happened to similar drugs?

2 of 13 similar drugs in Polycystic Ovary Syndrome were approved

Approved (2) Terminated (4) Active (7)
✅Placebo + EverolimusNovartisApproved
✅3 mg DRSP/20 μg EEBayerApproved
🔄Metformin XR + Saxagliptin + Saxagliptin-Metformin XRAstraZenecaPhase 3
🔄Exenatide once weekly (EQW ) + Dapagliflozin (DAPA) + EQW plus DAPA + Dapagliflozin plus Glucophage (MET ER) + Phentermine /Topiramate (PHEN/ TPM) ERAstraZenecaPhase 3
🔄Lisinopril + Telmisartan + PlaceboMerckPhase 3
🔄Lisinopril + Telmisartan + PlaceboMerckPhase 3
🔄Cetrorelix acetate + Cetrorelix acetate + Recombinant Human Choriogonadotropin (r-hCG) + Recombinant human follicle stimulating hormone (r-hFSH)MerckPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01118598ApprovedCompleted

Competing Products

20 competing products in Polycystic Ovary Syndrome

See all competitors
ProductCompanyStageHype Score
Tildacerfont + PlaceboSpruce BiosciencesPhase 2
17
ABBV-CLS-628 + PlaceboAbbViePhase 2
42
Elagolix + PlaceboAbbViePhase 2
35
Metformin XR + Saxagliptin + Saxagliptin-Metformin XRAstraZenecaPhase 3
40
Exenatide once weekly (EQW ) + Dapagliflozin (DAPA) + EQW plus DAPA + Dapagliflozin plus Glucophage (MET ER) + Phentermine /Topiramate (PHEN/ TPM) ERAstraZenecaPhase 3
40
AZD1613 - Part A + Placebo - Part A + AZD1613 - Part B + Placebo - Part BAstraZenecaPhase 1
36
AZD4901 (oral) + Placebo to match AZD4901AstraZenecaPhase 2
35
IVF Antagonist ProtocolMerckPre-clinical
22
Lisinopril + Telmisartan + PlaceboMerckPhase 3
40
Lisinopril + Telmisartan + PlaceboMerckPhase 3
40
Cetrorelix acetate + Cetrorelix acetate + Recombinant Human Choriogonadotropin (r-hCG) + Recombinant human follicle stimulating hormone (r-hFSH)MerckPhase 3
40
Gonal-f® + Long GnRH agonist + GnRH antagonistMerckPre-clinical
26
Placebo + EverolimusNovartisApproved
43
LIK066 + PlaceboNovartisPhase 2
35
Octreotide + PlaceboNovartisPhase 2/3
38
Everolimus + Calcineurin inhibitors maintenanceNovartisPhase 3
40
Everolimus + Octreotide LARNovartisPhase 2
35
Atorvastatin + PlaceboPfizerPre-clinical
26
RapamunePfizerPhase 1/2
32
SirolimusPfizerPhase 2/3
34